| Systematic (IUPAC) name | |
|---|---|
| (2E)-N-[(5α,6β)-17-(cyclopropylmethyl)- 3,14-dihydroxy- 4,5-epoxymorphinan- 6-yl]- 3-(3-furyl)- N-methylacrylamide | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | intravenous |
| Identifiers | |
| CAS number | 152658-17-8 |
| ATC code | V03AX02 |
| PubChem | CID 6445230 |
| IUPHAR ligand | 1651 |
| UNII | XC41AVD567 |
| Synonyms | TRK-820 |
| Chemical data | |
| Formula | C28H32N2O5 |
| Mol. mass | 476.564 g/mol |
| |
|
Nalfurafine (INN and USAN;[1] also known as AC-820, TRK-820; trade name Remitch) is a κ-opioid receptor agonist marketed as a treatment for uremic pruritus in people undergoing hemodialysis.[2]
As of January 2010[update], it is also being investigated for the treatment of pruritus in patients with chronic liver disease.[3]
| This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)